Document Detail


Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
MedLine Citation:
PMID:  20601804     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management through identification of molecular targets and prognostic factors to overcome the limits of efficacious chemotherapy delivery.
Authors:
Eirini Merika; Konstantinos N Syrigos; Muhammad Wasif Saif
Related Documents :
21861944 - Sexuality in institutionalized elderly persons: a systematic review of argument-based e...
20017714 - International society for cell and gene therapy of cancer 2009 annual meeting held in c...
10757924 - Some tips on preparing slides.
20302884 - 2nd german-french dna repair meeting - dna damage and repair in ageing and degenerative...
21169714 - November 2010 abstracts.
19812514 - Muscle forces or gravity--what predominates mechanical loading on bone? introduction.
Publication Detail:
Type:  Journal Article; Review     Date:  2010-07-05
Journal Detail:
Title:  JOP : Journal of the pancreas     Volume:  11     ISSN:  1590-8577     ISO Abbreviation:  JOP     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-05     Completed Date:  2010-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101091810     Medline TA:  JOP     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  328-30     Citation Subset:  IM    
Affiliation:
West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*,  genetics
Antineoplastic Agents / administration & dosage*
Chicago
Congresses as Topic
Drug Delivery Systems / methods*
Humans
Medical Oncology / methods,  trends
Models, Molecular
Pancreatic Neoplasms / drug therapy*,  genetics
Pharmacogenetics / methods*
Societies, Medical / organization & administration
Tumor Markers, Biological / antagonists & inhibitors,  genetics,  physiology
United States
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel Agents for the Treatment of Pancreatic Adenocarcinoma: Any Light at the End of the Tunnel? Hig...
Next Document:  Pancreatic Cancer and Thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. ...